ArticleAmerican journal of translational research2021
The effect of TACE in combination with thalidomide-mediated adjuvant therapy on the levels of VEGF and bFGF in patients with hepatocellular carcinoma.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- The efficacy and safety analysis of D-TACE combined with donafenib and tislelizumab in recurrent hepatocellular carcinoma after surgery.Scientific reports · 2025Article
- Thermal ablation for pulmonary oligometastases from hepatocellular carcinoma: initial experience and retrospective study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Expression and clinical significance of NLRC5 in hepatocellular carcinoma.Cancer biology & therapy · 2024Article
- Novel risk model based on angiogenesis-related lncRNAs for prognosis prediction of hepatocellular carcinoma.Cancer cell international · 2023Article
- SALL4 promotes angiogenesis in gastric cancer by regulating VEGF expression and targeting SALL4/VEGF pathway inhibits cancer progression.Cancer cell international · 2023Article
- Review
- A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE.Journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of transcatheter arterial chemoembolization (TACE) combined with thalidomide-mediated adjuvant therapy on the expression levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in hepatocellular carcinoma (HCC) patients.
methodsA prospective study was designed, by which 134 HCC patients from our hospital who underwent treatment were selected and randomly divided into an observation group and a control group, 67 participants per group. The control group was administered hepatic TACE, while the observation group was given TACE in combination with thalidomide. The total disease control rate (DCR) and the rate of adverse effects were analyzed and compared between the two groups of patients. The expression levels of CD3
resultsThe rate of adverse effects and DCR in the control group were 44.78% and 61.19%, respectively, whereas these rates were 22.39% and 89.55% in the observation group, respectively. Of note, the differences in terms of the rate of adverse effects and DCR were statistically significant between the two groups (P<0.05). Before treatment, no significant difference was shown regarding the expression levels of CD3
conclusionTACE in combination with thalidomide-mediated adjuvant treatment has revealed a promising clinical outcome on HCC patients by downregulating the levels of VEGF and bFGF.
Indexed as
Identifiers
34150160PMC8205699W3176336704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.